IP Library Granted Patent US 10,874,334
Granted Patent B1
US 10,874,334 · App. 15/674,320 · Granted Dec 29, 2020

Methods and systems for quantification of blood-brain barrier permeation of glycosylated peptides

Inventors: Michael L. Heien (Tucson, AZ); Nicholas D. Laude (Tucson, AZ); Catherine L. Kramer (Tucson, AZ)
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
A61B5/14528A61B5/0002A61B10/0045A61K38/08A61M1/1603B01D61/246B01D61/30G01N30/02G01N30/7206G01N2030/027G01N2030/8822
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,334
App. No.
15/674,320
Granted
Dec 29, 2020
Kind
B1
Abstract

Methods and systems for quantifying blood brain barrier (BBB) permeation of glycosylated peptides. The methods and systems feature microdialysis probes and mechanisms for infusing preservative agents into the outflow tubes of the microdialysis probes. The preservative agents help reduce unwanted degradation of the glycosylated peptides or other compounds, which can lead to a more accurate and complete analysis of the outflow tube perfusate.

Claims (15)

1. A microdialysis probe system comprising:

a. a dialysis membrane;

b. an inlet tube fluidly connected to the dialysis membrane such that a dialysis solution flows to the dialysis membrane;

c. an outflow tube fluidly connected to the dialysis membrane such that outflow fluid flows away from the dialysis membrane;

d. an infuser tube fluidly connected to the outflow tube, the infuser tube directs a preservation fluid into the outflow tube, wherein the preservation fluid combines with the outflow fluid, the preservation fluid comprises a preservative agent that inhibits or reduces degradation of glycosylated peptides present in the outflow fluid in the outflow tube; and

e. a detection component downstream of the outflow tube, the detection component detecting endogenous opioid peptides (EOPs).

2. The probe system of claim 1 , wherein the probe system allows for quantification of the EOPs.

3. The probe system of claim 2 , wherein the probe system allows for quantification of the EOPs at concentrations of 10 pM or less.

4. The probe system of claim 2 , wherein the probe system has a detection limit of 1.5 amol.

5. The probe system of claim 1 further comprising:

a. a first syringe pump fluidly connected to the inlet tube, the first syringe pump pumps the dialysis fluid through the inlet tube to the dialysis membrane;

b. a second syringe pump fluidly connected to the infuser tube, the second syringe pump pumps the preservation fluid through the infuser tube to the outflow tube; and

c. a micro-tee adaptor placed after the microdialysis probe, the micro-tee adaptor combines the preservation fluid with the outflow fluid.

6. The probe system of claim 5 further comprising a fraction collector disposed downstream from wherein the preservation fluid and outflow fluid combine.

7. The probe system of claim 5 further comprising a multi-fluid-line swivel for integrating the inlet tube, the outflow tube, and the infuser tube.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: HEIEN, MICHAEL L.; LAUDE, NICHOLAS D.; KRAMER, CATHERINE L.
To: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 046358/0466 →
CONFIRMATORY LICENSE Recorded Sep 18, 2017
From: UNIVERSITY OF ARIZONA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043882/0361 →
Continuity (1)
Provisional Application 62373231 · Aug 10, 2016